Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564592 | 1.00 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL3873222 | 1.00 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL9193218 | 1.00 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL5762765 | 0.98 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL6858111 | 0.98 | HSD17B10 (1.00) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL24368139 | 0.98 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| Hydrochloric Acid SCHEMBL1128463 | 0.98 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL936468 | 0.98 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL15572215 | 0.98 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL2910021 | 0.98 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118425362-B | Organic acid metabolism marker for distinguishing wild and cultivated four-big domestic fish and application thereof | 中国水产科学研究院长江水产研究所 | 2024-12-10 | — | — | CN | claimed |
| CN-118425362-A | Organic acid metabolism marker for distinguishing wild and cultivated four-big domestic fish and application thereof | 中国水产科学研究院长江水产研究所 | 2024-08-02 | — | — | CN | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | claimed |
| CN-117402442-A | Antibacterial PVC decorative film and preparation method thereof | 黄山东仁新材料股份有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-114907288-B | Application of nitrobenzene compounds in preparation of pseudomonas aeruginosa quorum sensing inhibitor | 中国医学科学院医药生物技术研究所 | 2023-12-08 | — | — | CN | claimed |
| CN-117187810-A | Microetching roughening solution for high-frequency high-speed circuit board and application thereof | 上海天承化学有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-117143110-A | Tumor permeation type carrier-free nano-drug and preparation method and application thereof | 浙江大学 | 2023-12-01 | — | — | CN | claimed |
| CN-110964085-B | Preparation method of carfilzomib and derivatives thereof | 扬子江药业集团有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20220267372-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX PHARMACEUTICALS, INC. | 2022-08-25 | — | — | US | claimed |
| CN-1302300-A | Pyrrolo [1, 2-b]Pyridazine sPLA2Inhibitors | SHIONOGI & CO (JP) | 2001-07-04 | — | — | CN | claimed |
| EP-0730591-B1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | UPJOHN CO (US) | 1999-07-14 | — | — | EP | claimed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| US-5652238-A | WATER SOLUBILITY; ANTIMICROBIAL AGENTS EFFECTIVE AGAINST RESISTANT STAPHYLOCOCCI, ENTEROCOCCI, AND STREPTOCOCCI | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | claimed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | claimed |
| EP-0730591-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1996-09-11 | — | — | EP | claimed |
| WO-1995014684-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | THE UPJOHN COMPANY (US) | 1995-06-01 | — | — | WO | claimed |
| EP-0299973-B1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1992-06-17 | — | — | EP | claimed |
| EP-0299973-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. | UPJOHN CO (US) | 1989-01-25 | — | — | EP | claimed |
| WO-1987006133-A1 | ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-10-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267372-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB11 | HSD17B10 3937/4885KDM4E 2837/4885ALOX15 1330/4885 |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, FGB, SARS1 | HSD17B10 3697/4885KDM4E 4840/4885ALOX15 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.